Rege Nephro

Recent Finacing

Series B

Recent Raise

$151.3M

Rege Nephro develops iPSC-derived nephron progenitor cell therapies and small-molecule retinoic-acid-receptor agonists (RN-032, RN-014) for kidney diseases, leveraging CiRA iPSC technology from Kyoto University.

Founded 2019

Kyoto, Japan

11-50

Private

regenephro.co.jp

Highlights

Focus Areas

Biotechnology

Manufacturing

Medical

Rental

Recent Investors

C

I

Financials

$163.4M

Total Raised

2

Funding rounds

25

Investors

Team

Upgrade to view the team

See the team members at Rege Nephro.